253 filings
ARS
2023 FY
XCUR
Exicure Inc
11 Jun 24
Annual report to shareholders
5:18pm
DEF 14A
XCUR
Exicure Inc
Definitive proxy
11 Jun 24
12:12pm
10-K
2023 FY
XCUR
Exicure Inc
Annual report
6 Jun 24
4:23pm
8-K
XCUR
Exicure Inc
6 Jun 24
Exicure, Inc. Reports Full Year 2023 Financial Results
4:18pm
10-Q/A
2023 Q2
XCUR
Exicure Inc
Quarterly report (amended)
6 Jun 24
4:17pm
8-K
68l49gagijbru
23 May 24
Exicure, Inc. Received Nasdaq Notice of a Delisting Determination
4:18pm
8-K
nvvkj36
16 May 24
Exicure, Inc. Reports Third Quarter 2023 Financial Results
4:50pm
NT 10-Q
voelv67
15 May 24
Notice of late quarterly filing
4:45pm
8-K
15q4xu98 0dj4ylg
22 Apr 24
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K
4:20pm
NT 10-K
knpkwni5f7ua0r0o6
1 Apr 24
Notice of late annual filing
4:20pm
8-K
3pf5c701zfib
5 Feb 24
Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis
4:16pm
8-K
ugv65j6x731a1jnz
16 Jan 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:16pm
8-K
knfv 7omgs9
1 Dec 23
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
4:21pm
8-K
7nbwqlqut fa3k2bd
28 Nov 23
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q
4:19pm
NT 10-Q
eo0v50jkng l4w
14 Nov 23
Notice of late quarterly filing
4:28pm
8-K
da7b925d
6 Oct 23
Other Events
5:03pm